Cheraghipour Kourosh, Masoori Leila, Ezzatkhah Fatemeh, Salimikia Iraj, Amiri Sana, Makenali Ali Safar, Taherpour Farshad, Mahmoudvand Hossein
Razi Herbal Medicines Research Center, Lorestan University of Medical Sciences, Khorramabad, Iran.
Department of Laboratory Sciences, School of Allied Medicine, Lorestan University of Medical Sciences, Khorramabad, Iran.
Parasite Epidemiol Control. 2020 Oct 21;11:e00189. doi: 10.1016/j.parepi.2020.e00189. eCollection 2020 Nov.
The preferred treatment for management of toxoplasmosis is the combined use of pyrimethamine and sulfadiazine. However, there are a wide number of adverse side effects with these medications. Recent research has focused on the use of chitosan for the treatment of infections. This review was performed to obtain a better understanding of the and effects of chitosan on strains.
The current study was carried out according to the PRISMA guideline and registered in the CAMARADES-NC3Rs Preclinical Systematic Review and Meta-analysis Facility (SyRF) database. The search was performed in five scientific databases, including Scopus, PubMed, Web of Science, EMBASE, and Google Scholar, with date limits of 1992 to December 2019. The search was restricted to articles published in the English language. The words and terms searched were "", "Chitosan", "nanoparticles" and "anti-toxoplasmosis" with AND or OR.
Of 2500 manuscripts, 9 met the eligibility criteria for review. All studies used the RH strain of , with Me49 and PRU each included in one study. Five studies (56%) were performed , one study and 3 studies included and tests.
Considering the low toxicity and the high inhibitory potency of chitosan against , chitosan nanoparticles show potential as an alternative treatment for .
弓形虫病治疗的首选方法是联合使用乙胺嘧啶和磺胺嘧啶。然而，这些药物有很多不良副作用。最近的研究集中在壳聚糖用于治疗感染方面。进行本综述是为了更好地了解壳聚糖对弓形虫菌株的影响和作用。
本研究按照PRISMA指南进行，并在CAMARADES-NC3Rs临床前系统评价和荟萃分析工具（SyRF）数据库中注册。在五个科学数据库中进行检索，包括Scopus、PubMed、科学网、EMBASE和谷歌学术，时间限制为1992年至2019年12月。检索仅限于以英文发表的文章。检索的关键词和术语是“弓形虫病”、“壳聚糖”、“纳米颗粒”和“抗弓形虫病”，采用“与”或“或”的逻辑关系。
在2500篇手稿中，9篇符合综述的纳入标准。所有研究均使用弓形虫的RH菌株，Me49和PRU各有一项研究纳入。5项研究（56%）在体外进行，1项研究在体内进行，3项研究包括体外和体内试验。
考虑到壳聚糖对弓形虫的低毒性和高抑制效力，壳聚糖纳米颗粒显示出作为弓形虫病替代治疗方法的潜力。
